Trending Topic

6 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Grace Johanna Salazar Tamayo

Highlights Determining infection and multidrug resistance (MDR) rates continuously helps to detect the problem to be solved, including outbreaks. Cleaning and disinfection play an important role in preventing MDR and evaluating and correcting the process for better results. MDR control can only be achieved with various measures applied continuously and consistently by a group of […]

touchINFECTIOUS DISEASES

Education, Conference Coverage and Articles

Speciality Filter
Or View our Specialities Page

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore how point-of-care testing is transforming the management of sexually transmitted infections (STIs). Joined by Dr Libby van Gerwen, we discuss the rising global STI rates and the role these innovative tests play in addressing the issue. We also explore the challenges current point-of-care tests face and how next-generation advancements could further transform the future of STI diagnosis and treatment.

Mark CompleteCompleted
BookmarkBookmarked
Grace Johanna Salazar Tamayo

Highlights Determining infection and multidrug resistance (MDR) rates continuously helps to detect the problem to be solved, including outbreaks. Cleaning and disinfection play an important role in preventing MDR and evaluating and correcting the process for better results. MDR control ...

38 mins
touchIN CONVERSATION
Mark CompleteCompleted
BookmarkBookmarked

Two experts discuss best practices for antiretroviral therapy (ART) selection for people living with HIV.

38 mins
touchEXPERT OPINIONS
Mark CompleteCompleted
BookmarkBookmarked
Prof. Anne-Mieke Vandamme, Prof. José Arribas, Prof. Antonella Castagna

Watch three experts describe the HIV life cycle, the rationale for ART and how to manage ART resistance.

Want to be featured in touchReviews in Infectious Diseases?

Share your knowledge, influence clinical practices and enhance patient care in Infectious Diseases today!

  • Peer-reviewed, free-to-access
  • Accepting reviews, research and editorials
  • No article processing fees
  • Digital features and plain language summaries
  • Multichannel content distribution for maximum visibility
Mark CompleteCompleted
BookmarkBookmarked

The expansion of HIV treatment access during the past two decades, particularly in low- and middle-income countries, stands as a significant accomplishment in the field of public health.1 Currently, there are an estimated 30 million people on antiretroviral treatment for HIV ...

Mark CompleteCompleted
BookmarkBookmarked

Respiratory syncytial virus (RSV) is often of increased concern in the autumn and winter months, especially for women who are pregnant, or those with newborns.1 Worldwide, RSV is the second leading cause of death (second to malaria) in children during ...

Mark CompleteCompleted
BookmarkBookmarked

Vaginal symptoms are one of the most common reasons for women accessing acute healthcare in the USA.1 Vaginitis is most commonly evaluated based on clinical observations, including assessment of discharge characteristics, vaginal pH and, in some settings, microscopic examination of ...

Mark CompleteCompleted
BookmarkBookmarked

We are excited to introduce the latest edition of touchREVIEWS in Infectious Diseases. Our mission is to bring you thought-provoking interviews, reviews, editorials, case studies and original research within the realm of infectious diseases. We aspire to engage infectious disease ...

Mark CompleteCompleted
BookmarkBookmarked

The treatment of people with HIV (PWH)/hepatitis B virus (HBV) co-infection, especially those who have additional comorbidities requiring multiple drug therapies can be problematic. Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a co-formulated medication consisting of two components ...

Mark CompleteCompleted
BookmarkBookmarked

By sharing, listening and gaining an understanding of the real-life experiences of individuals living with a condition, clinicians and patients can better work together to improve care and outcomes and shape the healthcare system and policy of the future. Patient ...

Mark CompleteCompleted
BookmarkBookmarked

Despite being the most severe form of viral hepatitis, there is no FDA-approved therapy for chronic hepatitis delta (CHD).1 Patients with CHD can progress to cirrhosis, as early as 5–10 years after infection. Further complications can also develop, such as esophageal ...

Mark CompleteCompleted
BookmarkBookmarked

Article highlights Erythrasma is a common chronic superficial cutaneous bacterial infection caused by Corynebacterium minutissimum when conditions are conducive. Corynebacterium minutissimum produces coproporphyrin III (a phosphor) that emits a coral pink fluorescence under Wood’s lamp and helps confirm the ...

Mark CompleteCompleted
BookmarkBookmarked

HIV is a significant global health issue for which there is no cure. However, the availability of antiretroviral therapy (ART) has made it possible to effectively treat and prevent HIV infection, leading to a considerable decrease in associated deaths and ...

Mark CompleteCompleted
BookmarkBookmarked

Heavily treatment-experienced people living with HIV (HTE-PLWH) represent a minority of those living with HIV.1 While there is variability in the definitions of HTE-PLWH, its prevalence is estimated to be between 1 and 10% of the total number of people living with ...

38 mins
touchPANEL DISCUSSION
Mark CompleteCompleted
BookmarkBookmarked
Prof. Jens Lundgren, Prof. Marta Boffito, Ms Angelina Namiba

Watch three experts discuss how to optimize antiretroviral therapy for people living with HIV through an individualized approach to care

Mark CompleteCompleted
BookmarkBookmarked

The Russian invasion of Ukraine represents the largest humanitarian crisis that Europe has faced in decades. In the first 4 months of the war, over 9.9 million refugees crossed the Ukrainian border, and over 6.1 million Ukrainian refugees were registered across Europe.1 Before ...

Load More...

Editorial Board

Introducing the Editorial Board of touchREVIEWS in Infectious Diseases, who support our mission to advance medical knowledge and practice by ensuring the integrity, relevance, and impact of the content we publish. Together, we strive to foster a vibrant academic community and contribute to the continuous improvement of healthcare worldwide.

View All Members

Amesika Nyaku

Editor-in-Chief

HIV

Close Popup

Amesika Nyaku

Editor-in-Chief

Assistant Professor, Division of Infectious Diseases, Rutgers New Jersey Medical School, Newark, NJ, USA

Newark, NJ, USA

Biography

Amesika Nyaku, MD MS is an Assistant Professor in the Division of Infectious Diseases at Rutgers New Jersey Medical School and a physician-scientist. She provides clinical care for people living with HIV or other infectious diseases and substance use disorders. Her research interests lie at the intersection of HIV and substance use disorders. She focuses on 1) evaluating long-acting therapeutics for HIV and opioid use disorder, 2) the implementation of integrated care models for HIV and substance use disorders to improve health outcomes, and 3) increasing the inclusion and participation of racial/ethnic minorities in clinical trials research. She is also co-director of the Northern New Jersey Medication-Assisted Treatment Center of Excellence that is tasked with assisting the state in expanding access to medication-assisted treatment for opioid use disorder through education, novel service delivery and community collaboration.

Libby Van Gerwen

Editorial Board member

Libby Van Gerwen

Editorial Board member

Sexually Transmitted Infections

Close Popup

Libby Van Gerwen

Editorial Board member

Assistant Professor, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA

Birmingham, AL, USA

Biography

Dr Olivia Van Gerwen completed her internal medicine residency and chief residency at Tulane University in New Orleans, LA. She returned to her hometown of Birmingham, AL to pursue a fellowship in Infectious Diseases at UAB, which she completed in 2020 in addition to a post-doctoral fellowship in health services, outcomes, and effectiveness research. She is now an Assistant Professor in the University of Alabama at Birmingham (UAB) Division of Infectious Diseases. Olivia’s research focuses on HIV and STI prevention as well as comprehensive sexual health promotion among LGBTQ+ populations. Clinically, she enjoys providing sexual healthcare services to patients at the UAB Gender Health clinic, patients living with HIV at the UAB 1917 Clinic and is the Assistant Medical Director at the UAB Vaginitis Clinic.

Amesika Nyaku

Editor-in-Chief

Louis Picker

Editorial Board member

Louis Picker

Editorial Board member

Vaccines

Close Popup

Louis Picker

Editorial Board member

Associate Director of the Vaccine and Gene Therapy Institute, Senior Scientist in the Pathobiology and Immunology Division of the Oregon National Primate Research Center, and Professor in the Oregon Health & Science University’s Departments of Pathology and Molecular Microbiology and Immunolog, Portland, OR, USA

Portland, OR, USA

Biography

Dr Louis J Picker is currently the Associate Director of the Vaccine and Gene Therapy Institute, a Senior Scientist in the Pathobiology and Immunology Division of the Oregon National Primate Research Center, and a Professor in the Oregon Health & Science University’s Departments of Pathology and Molecular Microbiology and Immunology.  Dr Picker was recruited to OHSU in 2000 from the Department of Pathology at the University of Texas Southwestern Medical Center at Dallas where he served as a Principal Investigator, Medical Director of the Flow Cytometry and Clinical Immunology Laboratory, and Co-Director of the Division of Hematopathology and Immunology.  He received his medical degree at the University of California, San Francisco in 1982, did an internship, residency, and chief residency in Anatomic and Clinical Pathology at the Beth Israel Hospital and Harvard Medical School in Boston, Massachusetts from 1982-86, and received advanced training in Immunopathology and Experimental Pathology at Stanford University Medical Center in Palo Alto, California from 1986-89.  Dr Picker is known for his work elucidating human/nonhuman primate (NHP) memory T cell biology, T cell mediated mechanisms of protection against persistent pathogens, the immunopathogenesis of AIDS and tuberculosis, and HIV and TB vaccine development. 

Libby Van Gerwen

Editorial Board member

Christoph Boesecke

Editorial Board member

Christoph Boesecke

Editorial Board member

COVID & HIV

Close Popup

Christoph Boesecke

Editorial Board member

Infectious Diseases Specialist and Senior Lecturer, University of Bonn, Germany

Bonn, Germany

Biography

Christoph Boesecke MD completed his medical studies at Charité University in Berlin, Germany. He received his Doctorate in Medicine from the University of Hamburg, Germany for his research in acute HIV infection. He held a 2-year postgraduate position studying integrase inhibitors in acute and chronic HIV infection at the National Centre in HIV Epidemiology and Clinical Research (now The Kirby Institute) in Sydney, Australia. He is currently working as an Infectious Diseases Specialist and Senior Lecturer at the University of Bonn, Germany. His main areas of research are focused on co-morbidities and co-infections in HIV including Covid-19 and monkeypox.

Louis Picker

Editorial Board member

Mahmoud A. Ghannoum

Faculty Member
Advertisement
  • touchINFECTIOUS DISEASES touchINFECTIOUS DISEASES

    Register Now!

    Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

    • Save your progress for video
    • Keep track of your CME credits
    • Add personalised learning notes
    • Receive updates from course leaders and faculty
    • Be the first to hear about new and exciting interactive learning opportunities
    Close Popup